JP2015504051A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015504051A5 JP2015504051A5 JP2014549567A JP2014549567A JP2015504051A5 JP 2015504051 A5 JP2015504051 A5 JP 2015504051A5 JP 2014549567 A JP2014549567 A JP 2014549567A JP 2014549567 A JP2014549567 A JP 2014549567A JP 2015504051 A5 JP2015504051 A5 JP 2015504051A5
- Authority
- JP
- Japan
- Prior art keywords
- a1pi
- lung
- composition
- subject
- increased
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161581708P | 2011-12-30 | 2011-12-30 | |
| US61/581,708 | 2011-12-30 | ||
| PCT/IB2012/056616 WO2013098672A2 (en) | 2011-12-30 | 2012-11-22 | Alpha1-proteinase inhibitor for delaying the onset or progression of pulmonary exacerbations |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016197058A Division JP2017039745A (ja) | 2011-12-30 | 2016-10-05 | 肺の増悪の発現または進行を遅延させるためのアルファ１−プロテイナーゼ阻害剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015504051A JP2015504051A (ja) | 2015-02-05 |
| JP2015504051A5 true JP2015504051A5 (enExample) | 2015-08-06 |
Family
ID=47470050
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014549567A Pending JP2015504051A (ja) | 2011-12-30 | 2012-11-22 | 肺の増悪の発現または進行を遅延させるためのアルファ１−プロテイナーゼ阻害剤 |
| JP2016197058A Pending JP2017039745A (ja) | 2011-12-30 | 2016-10-05 | 肺の増悪の発現または進行を遅延させるためのアルファ１−プロテイナーゼ阻害剤 |
| JP2018010440A Pending JP2018104439A (ja) | 2011-12-30 | 2018-01-25 | 肺の増悪の発現または進行を遅延させるためのアルファ１−プロテイナーゼ阻害剤 |
| JP2019070581A Pending JP2019135243A (ja) | 2011-12-30 | 2019-04-02 | 肺の増悪の発現または進行を遅延させるためのアルファ１−プロテイナーゼ阻害剤 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016197058A Pending JP2017039745A (ja) | 2011-12-30 | 2016-10-05 | 肺の増悪の発現または進行を遅延させるためのアルファ１−プロテイナーゼ阻害剤 |
| JP2018010440A Pending JP2018104439A (ja) | 2011-12-30 | 2018-01-25 | 肺の増悪の発現または進行を遅延させるためのアルファ１−プロテイナーゼ阻害剤 |
| JP2019070581A Pending JP2019135243A (ja) | 2011-12-30 | 2019-04-02 | 肺の増悪の発現または進行を遅延させるためのアルファ１−プロテイナーゼ阻害剤 |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US9421248B2 (enExample) |
| EP (1) | EP2758065B1 (enExample) |
| JP (4) | JP2015504051A (enExample) |
| KR (1) | KR20140108516A (enExample) |
| CN (2) | CN107596359A (enExample) |
| AR (2) | AR088971A1 (enExample) |
| AU (1) | AU2012337241B2 (enExample) |
| BR (1) | BR112014007127A2 (enExample) |
| CA (1) | CA2844878C (enExample) |
| CL (1) | CL2014000722A1 (enExample) |
| ES (1) | ES2887358T3 (enExample) |
| IL (1) | IL231109B (enExample) |
| MX (1) | MX351189B (enExample) |
| MY (1) | MY166314A (enExample) |
| RU (1) | RU2635482C2 (enExample) |
| SG (2) | SG2014012066A (enExample) |
| UY (1) | UY34465A (enExample) |
| WO (1) | WO2013098672A2 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105592854A (zh) * | 2013-08-05 | 2016-05-18 | 杰拉德·沃尔曼 | 使吸烟的不利作用减少的新方法 |
| EP3236772A4 (en) * | 2014-12-22 | 2018-10-17 | Alexion Pharmaceuticals, Inc. | Methods of purifying recombinant proteins |
| EP3253406B1 (en) | 2015-02-05 | 2023-11-01 | Canem Holdings, LLC | Compositions for treating granulomatosis with polyangiitis |
| CA3054267A1 (en) * | 2017-02-21 | 2018-08-30 | Kamada Ltd. | Methods and uses of alpha 1-antitrypsin for early intervention in pulmonary diseases |
| US10663434B2 (en) * | 2017-03-31 | 2020-05-26 | Sonix, Inc. | Wafer chuck |
| WO2020014326A1 (en) * | 2018-07-10 | 2020-01-16 | Ciancone Christopher V | Breath measurement device |
| WO2021028927A1 (en) * | 2019-08-15 | 2021-02-18 | Kamada Ltd | Combination of alpha-1-antitrypsin and steroids and uses therefor |
| CA3151997A1 (en) * | 2019-08-23 | 2021-03-04 | Ph Pharma Co., Ltd. | Use of a neutrophil elastase inhibitor in lung disease |
| EP4142775B1 (en) * | 2020-05-01 | 2026-03-25 | Ageronix SA | Treatment and/or prevention of a disease or a syndrome related to a virus infection |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE395611B (sv) | 1975-12-12 | 1977-08-22 | Draco Ab | Aerosolinhalationsanordning avsedd for inhalering genom ett inhaleringsmunstycke av farmakologiskt aktiva substanser |
| SE411705B (sv) | 1976-11-09 | 1980-02-04 | Draco Ab | Anordning for generering av en avskermad, vesentligen drivmedelsfri aerosol |
| EP0069715B1 (en) | 1981-07-08 | 1986-11-05 | Aktiebolaget Draco | Powder inhalator |
| US5218091A (en) | 1982-08-13 | 1993-06-08 | Zymogenetics, Inc. | Glycolytic promoters for regulated protein expression: protease inhibitor |
| US4667688A (en) | 1983-11-28 | 1987-05-26 | Francisco Roig | Mini pack of cigarettes |
| US4711848A (en) | 1984-03-14 | 1987-12-08 | Zymogenetics, Inc. | Site specific mutagenesis in alpha-1-antitrypsin |
| US4931373A (en) | 1984-05-25 | 1990-06-05 | Zymogenetics, Inc. | Stable DNA constructs for expression of α-1 antitrypsin |
| US4732973A (en) | 1984-06-14 | 1988-03-22 | Chiron Corporation | Active site modified protease α-1-antitrypsin inhibitors |
| JP2599585B2 (ja) | 1984-06-19 | 1997-04-09 | トランスジ−ン ソシエテ アノニム | ヒトα▲下１▼−アンチトリプシン誘導体及びその製造法 |
| US4697003A (en) | 1985-11-01 | 1987-09-29 | Miles Laboratories, Inc. | Method of preparing alpha-1-proteinase inhibitor |
| US5366894A (en) | 1986-06-30 | 1994-11-22 | Pharmaceutical Proteins Limited | Peptide production |
| US5093316A (en) | 1986-12-24 | 1992-03-03 | John Lezdey | Treatment of inflammation |
| JP2656944B2 (ja) | 1987-04-30 | 1997-09-24 | クーパー ラボラトリーズ | タンパク質性治療剤のエアロゾール化 |
| US5079336A (en) | 1989-06-23 | 1992-01-07 | The Trustees Of The University Of Pennsylvania | α-1-antichymotrypsin, analogues and methods of production |
| US5134119A (en) | 1990-10-16 | 1992-07-28 | Lezdey John | Treatment of inflammation using 358 substituted alpha-antitrypsin |
| US5915378A (en) | 1993-01-29 | 1999-06-29 | Aradigm Corporation | Creating an aerosolized formulation of insulin |
| US5672581A (en) | 1993-01-29 | 1997-09-30 | Aradigm Corporation | Method of administration of insulin |
| US5709202A (en) | 1993-05-21 | 1998-01-20 | Aradigm Corporation | Intrapulmonary delivery of aerosolized formulations |
| US5497763A (en) | 1993-05-21 | 1996-03-12 | Aradigm Corporation | Disposable package for intrapulmonary delivery of aerosolized formulations |
| DE69535897D1 (de) | 1994-03-07 | 2009-01-22 | Nektar Therapeutics | Verfahren und Zusammensetzung für die pulmonale Darreichung von Insulin |
| AU696387B2 (en) | 1994-05-18 | 1998-09-10 | Inhale Therapeutic Systems, Inc. | Methods and compositions for the dry powder formulation of interferons |
| US5610285A (en) | 1994-08-24 | 1997-03-11 | Bayer Corporation | Purification of α-1 proteinase inhibitor using novel chromatographic separation conditions |
| US5780014A (en) | 1995-04-14 | 1998-07-14 | Inhale Therapeutic Systems | Method and apparatus for pulmonary administration of dry powder alpha 1-antitrypsin |
| EP1736483A3 (en) | 1995-09-07 | 2008-07-30 | Pharming Intellectual Property BV | Purification of alpha-1 proteinase inhibitor |
| US5780440A (en) | 1996-06-17 | 1998-07-14 | Protease Sciences Inc. | Treatment of pulmonary disease with protease inhibitors |
| AT407114B (de) | 1997-06-10 | 2000-12-27 | Immuno Ag | Alpha 1-antitrypsin-präparation sowie verfahren zu deren herstellung |
| GEP20043260B (en) | 1998-03-16 | 2004-06-25 | Nectar Therapeutics | Aerosolized Active Agent Delivery and Device for Realization Thereof |
| US6093804A (en) | 1998-09-24 | 2000-07-25 | American National Red Cross | Method for purification of alpha-1 proteinase inhibitor |
| US6397838B1 (en) | 1998-12-23 | 2002-06-04 | Battelle Pulmonary Therapeutics, Inc. | Pulmonary aerosol delivery device and method |
| DE19953317C1 (de) * | 1999-11-05 | 2001-02-01 | Pari Gmbh | Inhalationsvernebler |
| US6462180B1 (en) | 1999-11-24 | 2002-10-08 | Bayer Corporation | Method of preparing α-1 proteinase inhibitor |
| JP4426179B2 (ja) | 2000-12-18 | 2010-03-03 | アライバ ファーマシューティカルズ，インコーポレイティド | 多機能性プロテアーゼインヒビターおよびそれらの疾患治療における使用 |
| DK1664123T4 (da) | 2003-09-22 | 2012-03-05 | Kamada Ltd | Storskalafremstilling af alfa-1-proteinaseinhibitor og anvendelse deraf |
| PT1684719E (pt) * | 2003-11-14 | 2012-02-03 | Baxter Int | Composições de alfa-1-antitripsina e métodos de tratamento utilizando estas composições |
| US7914771B2 (en) * | 2004-03-09 | 2011-03-29 | Arriva Pharmaceuticals, Inc. | Treatment of chronic obstructive pulmonary disease by low dose inhalation of protease inhibitor |
| RU2433841C2 (ru) * | 2006-02-09 | 2011-11-20 | Пари Фарма Гмбх | Доставка в легкие альфа-1-ингибитора протеиназ |
| US20080078382A1 (en) | 2006-09-20 | 2008-04-03 | Lemahieu Edward | Methods and Systems of Delivering Medication Via Inhalation |
| EP1927373B1 (en) | 2006-11-30 | 2012-08-22 | PARI Pharma GmbH | Inhalation nebulizer |
| NZ590257A (en) * | 2008-07-18 | 2012-08-31 | Grifols Therapeutics Inc | Method of preparing alpha-1 proteinase inhibitor |
| CN102655876B (zh) * | 2009-11-03 | 2015-07-15 | 基立福疗法公司 | α-1蛋白酶抑制剂组合物、方法和试剂盒 |
-
2012
- 2012-11-22 BR BR112014007127A patent/BR112014007127A2/pt not_active IP Right Cessation
- 2012-11-22 ES ES12808897T patent/ES2887358T3/es active Active
- 2012-11-22 AU AU2012337241A patent/AU2012337241B2/en active Active
- 2012-11-22 SG SG2014012066A patent/SG2014012066A/en unknown
- 2012-11-22 WO PCT/IB2012/056616 patent/WO2013098672A2/en not_active Ceased
- 2012-11-22 CN CN201710789166.XA patent/CN107596359A/zh active Pending
- 2012-11-22 CA CA2844878A patent/CA2844878C/en active Active
- 2012-11-22 RU RU2014106758A patent/RU2635482C2/ru active
- 2012-11-22 MX MX2014001764A patent/MX351189B/es active IP Right Grant
- 2012-11-22 CN CN201280048668.2A patent/CN103889436A/zh active Pending
- 2012-11-22 US US14/369,662 patent/US9421248B2/en active Active
- 2012-11-22 SG SG10201610913PA patent/SG10201610913PA/en unknown
- 2012-11-22 KR KR1020147006804A patent/KR20140108516A/ko not_active Ceased
- 2012-11-22 MY MYPI2014700341A patent/MY166314A/en unknown
- 2012-11-22 EP EP12808897.8A patent/EP2758065B1/en active Active
- 2012-11-22 JP JP2014549567A patent/JP2015504051A/ja active Pending
- 2012-11-23 AR ARP120104411A patent/AR088971A1/es not_active Application Discontinuation
- 2012-11-23 UY UY0001034465A patent/UY34465A/es not_active Application Discontinuation
-
2014
- 2014-02-24 IL IL231109A patent/IL231109B/en active IP Right Grant
- 2014-03-24 CL CL2014000722A patent/CL2014000722A1/es unknown
-
2016
- 2016-10-05 JP JP2016197058A patent/JP2017039745A/ja active Pending
-
2018
- 2018-01-25 JP JP2018010440A patent/JP2018104439A/ja active Pending
-
2019
- 2019-04-02 JP JP2019070581A patent/JP2019135243A/ja active Pending
- 2019-10-29 AR ARP190103126A patent/AR116887A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2014106758A (ru) | Ингибитор альфа1-протеиназы для задержки начала или прогрессирования легочных обострений | |
| Caramori et al. | Pharmacology of airway inflammation in asthma and COPD | |
| CA2716936C (en) | Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations | |
| Hirst et al. | A comparison of the lung deposition of budesonide from Easyhaler®, Turbuhaler® and pMDI plus spacer in asthmatic patients | |
| US10940110B2 (en) | Method and system for the treatment of chronic COPD with nebulized anticholinergic administrations | |
| CA2518794A1 (en) | Compositions and methods for treating emphysema | |
| Noone et al. | Airway deposition and clearance and systemic pharmacokinetics of amiloride following aerosolization with an ultrasonic nebulizer to normal airways | |
| Thorsson et al. | Factors guiding the choice of delivery device for inhaled corticosteroids in the long-term management of stable asthma and COPD: focus on budesonide | |
| Jiang et al. | The effect of ventilator mask atomization inhalation of ipratropium bromide and budesonide suspension liquid in the treatment of COPD in acute exacerbation period on circulating levels of inflammation and prognosis. | |
| Berg et al. | In vitro delivery of budesonide from 30 jet nebulizer/compressor combinations using infant and child breathing patterns | |
| Liang et al. | Inhaled therapies for asthma and chronic obstructive pulmonary disease | |
| Lin et al. | Aerosol delivery during spontaneous breathing with different types of nebulizers-in vitro/ex vivo models evaluation | |
| Reychler et al. | Comparison of lung deposition of amikacin by intrapulmonary percussive ventilation and jet nebulization by urinary monitoring | |
| CN111610261B (zh) | 一种筛选适用于β2受体激动剂的雾化装置的方法 | |
| Vp et al. | A novel metered dose inhalation formulations with formoterol 6 Mcg and beclomethasone 200 Mcg by using breath actuated inhaler | |
| Cherian et al. | Efficacy of swiss ball exercise to improve exercise tolerance and chest expansion in chronic obstructive pulmonary disease | |
| Abadelah | Effect of inhalation manoeuvre parameters in-vitro and ex-vivo on the dose emission and the aerodynamic characteristics of formoterol and indacaterol from marketed dry powder inhalers | |
| CA2872569C (en) | Uses of antagonists of hyaluronan signaling | |
| Christensen et al. | Safety and Efficacy of Inhaled Natural Product Powders That Enhance Mucociliary Clearance | |
| CN104363910A (zh) | 慢性阻塞性肺疾病改善剂 | |
| Annapu et al. | A REVIEW OF RECENT ADVANCES IN THE DEVICES FOR THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE | |
| Mirici et al. | A questionaire study investigating the knowledge and behaviour by physicians about use of nebuliser | |
| Nenna et al. | Position Paper on short-acting beta-2 agonists for acute wheezing episodes in children aged below 6 years. A statement proposed by the Italian Pediatric Respiratory Society (Società Italiana per le Malattie Respiratorie Infantili, SIMRI) Asthma Committee and approved by the SIMRI Advocacy Council and Executive Committee | |
| Cole et al. | C49 COPD: TREATMENT: Inhaled 7% Hypertonic Saline Is Safe To Administer In Patients With Moderate To Severe Chronic Obstructive Pulmonary Disease (COPD) | |
| Takita et al. | A59 EPIDEMIOLOGY OF AIRWAYS AND CHRONIC LUNG DISEASES: Effectiveness Of Training Patients In The Accurate Use Of Inhalers For The Treatment Of Bronchial Asthma Via Dvd |